Cancer immunotherapy is an innovative treatment for tumors today. In various experiments
and clinical studies, it has been found that immunotherapy does have incomparable …

The interaction of programmed cell death 1 ligand 1 (PDL1) with its receptor programmed
cell death 1 (PD1) inhibits T cell responses, and blockade of this interaction has proven to …

As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of
immunotherapy in recent years. They have extraordinary antitumor potential and prospects …

The immune checkpoint pathway consisting of the cell membrane-bound molecule
programmed death protein 1 (PD-1) and its ligand PD-L1 has been found to mediate …

Recent introduction of monoclonal antibodies targeting immune checkpoints to harness
antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic …

Programmed death protein 1 (PD-1) interaction with PD-L1 deliver immunosuppressive
environment for tumor growth, and its blockade with directed monoclonal antibodies (anti …

Simple Summary Natural killer cells are innate cytotoxic lymphocytes that play a key role in
the anti-tumor immune response. In the tumor microenvironment, however, the effector …

Co-inhibitory B7-CD28 family member proteins negatively regulate T cell responses and are
extensively involved in tumor immune evasion. Blockade of classical CTLA-4 (cytotoxic T …

The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for
neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes …

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option
for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor …